Clinical Trial Update: Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (46101/P06459/MK-8265-012) [Phase 3]

View source ↗

Summary

Phase 3 dose-finding trial of Org50081 (Esmirtazapine) for vasomotor symptoms in menopause completed; results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Menopause
• Vasomotor Symptoms

Drugs mentioned

• Org50081 (Esmirtazapine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Menopause, Vasomotor Symptoms | Phase 3 | Status: COMPLETED | Results posted: 2014-06-30